Get started

CUSTODIAN

Coinbase wave C underway NASDAQ:COIN Price appears to be completing wave C of IV, a corrective pattern to the downside expected to be shallow. Wave IV are often shallow ending no further than the 0.5 Fibonacci retracement. This is just below the S2 pivot and High Volume Node support. 0.382 is the higher probability target for the end of the downwards move aligning with a swing below the daily 200EMA and S1 pivot. Daily RSI has room to fall. Breaking wave B would suggest a new bull move is underway.
NASDAQ:COIN
by Maddox_Metrics
COIN Much higher to comeCoinbase had a shallow pullback in wave (II) after running 10x in wave (I). Wave (II) was expected to reach the 0.618 Fibonacci retracement but was front run above the 0.5 demonstrating long term strength. R5 weekly pivot target is now $841 which is expected to be hit if we get tailwind momentum in wave (III). Price appears to be finding a bottom locally and preparing for the next leg up into price discovery. RSI has plenty of room for months of overextension in price. 🎯 Terminal target for the business cycle could see prices as high as $800 based on the weekly pivots 📈 Weekly RSI is oversold with no divergence and can remain here for months as price keeps increasing. 👉 Analysis is invalidated below wave (II), $148
NASDAQ:COIN
by Maddox_Metrics
MSTR still in wave 4 rangeNASDAQ:MSTR Price is still in a wave (IV) which are expected to be long and drawn out, yet shallow which is what we have here. I don’t expect wave (V) to kick in until Bitcoin moves. Wave (V) has an expected of the R3 daily pivot at $1039 but will overextend if Bitcoin does. Price has fallen out of the lower channel boundary and sitting at the weekly pivot, still above the weekly 200EMA so the outlook us bullish. wave (4) may complete at the 0.236 Fibonacci retracement at $203. For now I am waiting to see what happens before entering but believe good opportunities are setting up. Safe trading
NASDAQ:MSTR
by Maddox_Metrics
Coinbase Bottom in, new all time high coming?NASDAQ:COIN had a deep pullback after its recent bullish move but caught a large bid by the end of the week leaving a long lower wick. It appears the bottom is in but investors should be cautious as price is below resistance major resistance High Volume Node and R1 weekly pivot. If the pullback is complete then we have a very shallow wave 2 within wave (II) and can expect much higher targets perhaps in the $1000s before the end of this business cycle. There will resistance at the upper boundary and R3 weekly pivot around $600 and a breakout above that area will signal we go higher. RSI has plenty of room for months over overextension in price. I will be looking to add a long so look out for the signal in my Trade Planning Substack. Safe trading
NASDAQ:COIN
by Maddox_Metrics
COIN Still following the plan.... nothing changedNASDAQ:COIN was expected to test the High Volume Node and channel upper boundary after its breakout as support. That happened Friday and touched it precisely during the market chaos we expect to reverse back to trend this week. Wave V is underway, wave IV completed at the 0.382 Fibonacci retracement and High Volume Node - a high probability area for a bottom. RSI tapped overbought but no bearish divergence. The gap has been filled and could market a reversal point lower on the macro and we should watch carefully but the trend is up for now. Safe trading
NASDAQ:COIN
by Maddox_Metrics
COIN Wave III underway into all time high!Elliot Wave (III) is still underway after wave (II) completed at the weekly 200EMA. Coinbase had a huge bullish engulfing candle this week, closing price above the High Volume Node and R1 weekly pivot - a strong bullish signal! Price first tested the High Volume Node support and 0.382 Fibonacci retracement, $270. Characteristic of wave 3 shallow pullbacks. Weekly RSI has reset to the channel EQ and crossing bullishly giving price room to extend upwards! Safe trading
NASDAQ:COIN
by Maddox_Metrics
MSTR Wave II bottom?NASDAQ:MSTR is finally catching a bid from the triple support zone of the Fibonacci golden pocket, S1 pivot and High Volume Node. It must overcome the daily 200EMA to add confidence to a reversal and wave II bottom being in. Daily RSI has printed bullish divergence from oversold. Vanguard disclosed massive MSTR holdings ad the sentiment is awful online adding confluence to a bottom soon. Wave III target is the R5 daily pivot $544, losing the support zone has a downside target of $232 Safe trading
NASDAQ:MSTR
by Maddox_Metrics
1
COIN wave 5 Underway!NASDAQ:COIN wave 4 appears complete at the expected Fibonacci retracement 38.2 and High Volume Node support. A local channel has formed which could be a bear pennant so bulls should watch out. A breakout of this would hit resistance at $360 High Volume Node and the first take profit area from my recent trade. Clearing this Nose will confirm wave 5 is underway to new all time highs $500+ RSI is flipping bullish from oversold and the dail 200EMA continues to rise. Safe trading
NASDAQ:COIN
by Maddox_Metrics
COIN Ready for Gap Fill?NASDAQ:COIN Coinbase looks ready for move up to at least fill the gap at $359 if not make new all time highs. Daily RSI printed bullish divergence and price broke out yesterday into bullish market structure. A break above the High Volume Node resistance could see new all time highs sooner than expected! Analysis is invalidated if we drop below the swing low and that will continue my previous analysis downwards with a target of the ascending 200EMA, High Volume Node support, S1 Pivot at $282. Safe trading
NASDAQ:COIN
by Maddox_Metrics
$MSTR shallow wave 2 underway before explosive move ?MicroStrategy has been caught in a range since Nov 2024 possibly building momentum for a large breakout into price discovery, continuing its huge rally from 2024. Price appears to ave completed an Elliot wave 1 with wave 2 now underway with a target of the ascending daily 200EMA $340, the 0.382 Fibonacci retracement. Weekly RSI is currently showing bullish divergence but daily suggests we have one push lower to get to oversold! Bitcoin stocks have all had a decent retracement causing me to upgrade my Elliot Wave count to a completed macro wave 1 with wave 2 now underway, suggesting the best returns are still to come over the next months for this category asset class in wave 3! Analysis is invalidated if we go to new highs above $457 or lose $229 New long signals are certainly building in the DEMA PBR and Price Action strategies so keep an eye out on the Trade Signals Substack as we have made very food profits lately in these markets! Safe trading
NASDAQ:MSTR
by Maddox_Metrics
$COIN Price Action playing out exactly as expected!NASDAQ:COIN price action is following the plan laid out a few weeks ago. After the momentous rally into all time high I was expecting price to have a deep retracement to the weekly pivot point also the golden pocket Fibonacci retracement $240. That is what we got! This values would correspond with a swing below the major High Volume Node support resetting daily and weekly RSI. Daily RSI is already oversold so I am expecting a bounce for wave B of this wave 2 corrective wave with a target of the $350 High Volume Node major resistance. The weekly 200EMA is ascending and may meet us in the same area adding confluence but this would take a lot longer to play out. Alternatively, there is also a gap at $215-230 that never got filled at the larger degree golden pocket which would have me upgrade this pullback to wave 2 instead of wave 4. Bitcoin stocks have all had a decent retracement causing me to upgrade my Elliot Wave count to a completed macro wave 1 with wave 2 now underway, suggesting the best returns are still to come over the next months for this category asset class in wave 3! Analysis is invalidated if we go to new highs or lose $140. New long signals are certainly building in the DEMA PBR and Price Action strategies so keep an eye out on the Trade Signals Substack as we have made very food profits lately in these markets! Safe trading
NASDAQ:COIN
by Maddox_Metrics
$COIN Wave 4 pullback?NASDAQ:COIN had a tremendous run, a text book Elliot wave 3 but has confirmed bearish divergence on the daily RSI. The trend is strong so wave 4 could be shallow, only reaching the previous all time high, High Volume Node and 0.236 Fibonacci retracement and daily pivot point between $322-345 Further decline brings up the High Volume Node support at 0.382 Fib retracement and ascending daily 200EMA! Also a highly probable scenario! Long term outlook remains around $600 target Safe trading.
NASDAQ:COIN
by Maddox_Metrics
$APYP R/M Into SleepX Could Make it a MASSIVE Runner PT: $1+On Nov 11th the company was successfully redomiciled to Nevada leaving just the last administrative steps towards the completion of the merger in December. twitter.com FRANCE Patent No. EP11819507.2 renewed in September twitter.com UK Patent No. EP2608717 renewed in September twitter.com Israeli Patent No. 224854 renewed in August twitter.com SleepX also has a portfolio of FIVE patents some of which are used in Fitbit: www.sleepxclear.com Intellectual property The company’s technology is protected by patents in order to provide a strong IP protection, one of the Company's most important assets. Its technology, applications and products, both in the medical and nonmedical fields, are protected by the laws of the United States and other jurisdictions worldwide. The Company's measurement technology utilizes a technique that measures a range of physical parameters as a function of time to a level of accuracy previously unattainable. The company's patent portfolio includes: ***SYSTEMS AND METHODS FOR SNORING DETECTION AND PREVENTION*** 1. ​HIGH-SENSITIVITY SENSORS FOR SENSING VARIOUS PHYSIOLOGICAL PHENOMENA, PARTICULARLY USEFUL IN ANTI-SNORING APPARATUS AND METHODS. 2. APPARATUS FOR USE IN CONTROLLING SNORING AND SENSOR UNIT PARTICULARLY USEFUL THEREN. 3. APPARATUS AND METHOD FOR DIAGNOSING SLEEP QUALITY 4. ESTIMATION OF SLEEP QUALITY PARAMETERS FROM WHOLE NIGHT AUDIO ANALYSIS 5. APPARATUS AND METHOD FOR DIGNOSING OBSTRUCTIVE SLEEP APNEA With distinctive innovative sensor technologies and algorithms, the Company is well-positioned to become a market leader in the snoring and obstructive sleep apnea treatment markets. twitter.com twitter.com The company also signed an agreement with NewsDirect's PR Firm for upcoming press release and marketing capabilities once everything has been finalized and completed. twitter.com www.sleepxclear.com
OTC:APYPLong
by StockGuild
$IFXY 62% Owned by Krisa/Cooley Biggest R/M or Holding CmpyKrisa Management and Carey Cooley own 62% of all Common Shares twitter.com www.otcmarkets.com They have continually said that this will be their biggest merger out of all their shells twitter.com twitter.com In their most recent update they announced that the launch is getting closer and is almost ready. They are also working on two acquisitions already turning $IFXY into possibly a holding company for multiple acquisitions. twitter.com "The $IFXY launch is getting closer. @CareyCooley is working hard on a deal to get his preferred COO on board. We are also trying to negotiate deals for our first two acquisitions."
OTC:IFXYLong
by StockGuild
$LEAS Major Pharma Potential with Acquisitions lined up PT .50PHARMIA’s $LEAS goal is to become a leading generics and super-generics company within 5 years. In executing its Plan, PHARMIA will take a three stage approach to the achievement of its goals. Stage 1 In the initial stage, PHARMIA will launch the company by acquiring MAs in Europe and ANDAs in the United States for generic products that are essential medicines in chronic short supply. PHARMIA will use 3rd parties in Germany to manufacture our oncology products and we will commercialize these “supply challenged” products which generally are older but “mainstay” life-saving medications for the treatment of cancer and infectious diseases, to include the drug shortages caused by the COVID-19 pandemic, where PHARMIA’s team has particular expertise. We will build the drug portfolio and the PHARMIA “brand name” during Stage 1. Stage 2 In the second stage of PHARMIA’s strategic plan, the company will develop and commercialize a portfolio of novel branded “super-generics” (super-generics are “better than generics” as they have added value and are patented). To achieve this goal, PHARMIA will capitalize on its ownership of the active pharmaceutical ingredients (“API”) acquired in Stage 1, and utilize the scientific and technical development expertise of its team members to reformulate the API of those generics into patented formulations. The goal is to create novel, patentable formulations with novel and improved characteristics (such as extended release, dissolvable films and implants, multiple drug combinations in one pill, etc.) that are more patient friendly, and more easily administered. The development of a portfolio of “super-generics” during Stage 2 will be a major revenue driver going forward. This “value add” will enhance patient compliance and therapeutic outcomes, differentiating PHARMIA pipeline from the competition. Also during Stage 2, the acquisition and development of biologic medicines (“antibodies”) targeting oncology will have begun, with the company already licensing three antibodies that have been fully developed and are on the market in several countries. It is PHARMIA objective to start and complete Phase 3 clinical trials of each “biosimilar” antibody targeting breast cancer, colorectal cancers, brain cancers, and several other solid tumors. Stage 2 is an important growth phase for the company. Stage 3 In the third stage of growth, PHARMIA will focus its attention on acquiring its own manufacturing facilities in the USA for the production of Active Pharmaceutical Ingredients (APIs) and final, formulated Drug Product dosage forms. This will enable the company to totally control the whole supply chain process and also expand its portfolio of products that are, or are expected to be, in chronic short supply or suffering from ongoing quality issues when supplied from outside the USA or Europe. With its own manufacturing infrastructure in place, PHARMIA will have the capability to meet supply demand by expeditiously switching manufacturing from one product to another in the same facility with only minor process changes required. The company will expand its sterile injectable drug manufacturing capabilities and its solid dosage form (super-generics) capacity during Stage 3. Starting with high quality but low-cost, affordable generic drugs treating deadly diseases, the second phase of grow is by employing pharmaceutical drug delivery technologies to enhance and improve the generic drug incorporated in the drug formulation as a “super-generic”. Our super-generics employ a technology called “3-D screen printing” of drugs with extended release properties and will provide a sustained drug level within the “therapeutic window” for once-a-day dosing. A single pill containing three or four medicines that can be taken once-a-day, and this approach provides the patient a lower “pill burden” and this will result in better compliance in taking the medicine and overall improved care of the patient. The company is working on 3-D screen-printed medicines with novel dissolution and release characteristics. 3-D screen-printing technology opens up new, flexible and versatile options for the pharmaceutical industry in the manufacturing process of their products. Thousands or even millions of medical doses can be manufactured per machine per year. The 3-D screen-printing process allows for many different kinds of shapes, sizes and compositions. We are committed to maintaining our entire business operations including the 3-D screen printing commercial manufacturing in America, Canada, and/or Europe (Ireland and Germany), and we will continue to build strong, lasting relationships with European and our Nation’s largest pharmacy chains, wholesalers, and distributors. Essential Medicines – Affordable Prices investorshub.advfn.com Dr. Joseph Sinkule Co-Founder, Chief Executive Officer (CEO) and Director www.pharmia-inc.com Strategic Asset Leasing Inc. Announces Cryptocurrency Launch Press Release | 10/06/2020 Strategic Asset Leasing Inc. Announces Cryptocurrency Development Press Release | 10/02/2020 Strategic Asset Leasing Inc. Enters Into MOU Press Release | 09/30/2020 Strategic Asset Leasing Inc. Announces New Subsidiary Press Release | 09/29/2020 Strategic Asset Leasing Inc. Enters Into Additional LOI Press Release | 09/25/2020 Strategic Asset Leasing Inc. Joins Open Source Projects Press Release | 09/24/2020
LLong
by StockGuild
$DLPX $7 Mil+ HQ and Sub of NASDAQ $AIRT On the Move Flwg UpdtsTaken from their website: “Delphax Solutions, Inc. is a business unit of holding company AIR T, INC. , which has been established since 1980.” www.delphaxsolutions.com $AIRT is currently trading at $26.77 This statement is from the Financial Q10 of February 12, 2021 AIRT: Type of Revenue Nature, Timing of Satisfaction of Performance Obligations, and Significant Payment Terms Product Sales The Company generates revenue from sales of various distinct products such as parts, aircraft equipment, >>>printing equipment<<<, jet engines, airframes, and scrap metal to its customers. A performance obligation is created when the Company accepts an order from a customer to provide a specified product. Each product ordered by a customer represents a performance obligation. Here is the link for the location of its HQ and you will see the warehouse and the sign Delphax. The warehouse building alone should be worth more than $7 million. See it yourself: goo.gl
OTC:DLPXLong
by StockGuild